SanBio Presents At Annual European Stroke Organisation Conference

SAN FRANCISCO & GLASGOW, Scotland--(BUSINESS WIRE)--SanBio, a leading regenerative medicine company focused on the discovery and development of new regenerative cell therapies, today announced one of its clinical investigators presented at the 1^st Annual European Stroke Organisation conference, a meeting of stroke researchers, physicians, societies and lay organizations from across Europe. The conference takes place April 17 through 19 in Glasgow, Scotland.

“Clinical Improvement and Cortical Flair Hyperintensity Associated With Stereotactic Intracranial Injection of Modified Bone Marrow-Derived Mesenchymal Stem Cells (SB623) in Chronic Stroke Patients”

The presentation, “Clinical Improvement and Cortical Flair Hyperintensity Associated With Stereotactic Intracranial Injection of Modified Bone Marrow-Derived Mesenchymal Stem Cells (SB623) in Chronic Stroke Patients,” will be given by Lawrence Wechsler, MD, professor of neurology and neurological surgery at the University of Pittsburgh School of Medicine and founding director of the University of Pittsburgh Medical Center (UPMC) Stroke Institute. The presentation took place during the “Rehabilitation and Recovery” scientific session on Friday, April 17.

At the conference, SanBio also is presenting a poster regarding the safety outcomes of its Phase 1/2A clinical trial, titled, “Safety of Stereotactic Intracranial Injection of Modified Bone Marrow-Derived Mesenchymal Stem Cells (SB623) in Chronic Stroke Patients: A Phase 1/2A Study.”

About SanBio

SanBio is based in Tokyo, with a United States headquarters in San Francisco. SanBio’s research focuses on harnessing the power of adult stem cells to provide new therapeutic options for the millions of people suffering from chronic stroke and other debilitating neurological disorders. Its proprietary stem cell therapy, SB623, is in Stage 2 clinical trials for treatment of chronic stroke and is expected to begin Stage 2 clinical trials for treatment of traumatic brain injury later in 2015.